DNL593 clinical trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

This study is testing a new medicine called DNL593 for frontotemporal dementia (FTD-GRN). It aims to see if it's safe, how the body handles it, and if it helps people with this specific type of dementia, compared to a dummy drug.